Plain-English translation of NCT05739045 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing nivolumab—an immunotherapy drug that helps your immune system fight cancer—combined with chemotherapy (oxaliplatin and S-1) in people with locally advanced stomach or gastroesophageal junction cancer. The treatment is given before surgery to shrink the tumor, then again after surgery to help prevent the cancer from coming back. Researchers want to see if this combination approach leads to better outcomes than standard treatment alone.
Currently, stomach cancer is very serious, and existing treatments don't work well enough for many patients. This trial is exploring whether adding this immunotherapy medication to chemotherapy—both before and after surgery—could help more people achieve complete remission and live longer.
Over about 12 months, you would receive 3 cycles of the medication and chemotherapy by infusion before surgery (typically 6–9 weeks). Then you'd have your surgery 2–6 weeks after finishing this initial treatment. After surgery, you'd receive 3 more cycles of the same medication and chemotherapy combination (starting at least 4 weeks after your operation), followed by 11 cycles of the immunotherapy medication alone to maintain the effect. Blood tests and imaging would monitor how well the treatment is working and how your body is tolerating it.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Xiangdong Cheng
Enrollment target
~46 participants
Started
November 2022
Primary completion
December 2024
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cheng Xiangdong
Zhejiang Cancer Hospital